Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Triangle Pharmaceuticals (NasdaqNM:VIRS)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 21Price hit new 52-week low ($2.25)
Aug  6Earnings Announcement
Location
4 University Place
4611 University Drive
Durham, NC 27707
Phone: (919) 493-5980
Fax: (919) 493-5925
Employees (last reported count): 170
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 66%
·Over the last 6 months:
 · one insider buy; 1.30M shares (4.2% of insider shares)
·Institutional: 41% (121% of float)
(134 institutions)
·Net Inst. Buying: 2.56M shares (+11.41%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Triangle Pharmaceuticals, Inc. develops new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus. The Company has an existing portfolio of six licensed drug candidates in clinical trials and several drug candidates that are in a pre-clinical stage or for which it has an option to acquire a license. Its portfolio include Coviracil (emtricitabine), a nucleoside analogue that has been shown to be a potent inhibitor of HIV and hepatitis B virus replication in laboratory studies; Coactinon (emivirine), a non-nucleoside reverse transcriptase inhibitor; DAPD, a purine dioxolane nucleosides currently in development for the treatment of viral diseases; Mozenavir dimesylate, a potent, selective inhibitor of the HIV-1 protease; clevudine, shown to be a potent inhibitor of hepatitis B virus replication in laboratory studies; and immunostimulatory sequences candidates for hepatitis B.
More from Market Guide: Expanded Business Description

Financial Summary
VIRS is a pharmaceutical company engaged in the development of new drug candidates primarily in the anti-viral area, with a particular focus on therapies for HIV. For the six months ended 6/30/01, revenues fell 8% to $3.5 million. Net loss fell 24% to $44 million. Results reflect an extension of the development period for which collaborative revenues are amortized, offset by lower manufacturing costs and the absence of a $5.4 million purchased research and development charge.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Pay

David Barry, M.D., 56
Chairman, CEO
$447K
Chris Rallis, J.D., 46
Pres, COO, Director
495K
Robert Amundsen, Jr.
Exec. VP, CFO
--  
Andrew Finkle
Exec. VP, Gen. Counsel, Sec.
--  
Paul Dreyer
Exec. VP, Commercial Operations
--  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:VIRSAs of 31-Aug-2001
Price and Volume
52-Week Low
on 21-Aug-2001
$2.25 
Recent Price$3.20 
52-Week High
on 18-Sep-2000
$9.469
Beta0.70 
Daily Volume (3-month avg)103.9K
Daily Volume (10-day avg)203.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-64.4%
52-Week Change
relative to S&P500
-52.3%
Share-Related Items
Market Capitalization$154.8M
Shares Outstanding48.4M
Float16.4M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.51 
Earnings (ttm)-$2.34 
Earnings (mrq)-$0.45 
Sales (ttm)$0.17 
Cash (mrq)$1.29 
Valuation Ratios
Price/Book (mrq)6.28 
Price/EarningsN/A 
Price/Sales (ttm)18.95 
Income Statements
Sales (ttm)$6.98M
EBITDA (ttm)-$98.6M
Income available to common (ttm)-$95.4M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-101.57%
Return on Equity (ttm)-255.92%
Financial Strength
Current Ratio (mrq)1.53 
Debt/Equity (mrq)0 
Total Cash (mrq)$62.4M
Short Interest
As of 8-Aug-2001
Shares Short890.0K
Percent of Float5.4%
Shares Short
(Prior Month)
852.0K
Short Ratio13.69 
Daily Volume65.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.